Loading
Clifford Hudis is Chief Executive Officer of the American Society of Clinical Oncology (ASCO), a role he has held since 2016, and was formerly Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center. A breast oncologist, he served as ASCO president in 2013 to 2014 and now oversees the society's meetings, journals, guidelines and CancerLinQ. His papers include a New England Journal of Medicine review of trastuzumab's mechanism of action and clinical use and the STEEP proposal for standardised efficacy end point definitions in adjuvant breast cancer trials. His work spans HR-positive and HER2-positive breast cancer, professional society leadership and health policy.
| Title | Journal | Year |
|---|---|---|
| Trastuzumab--mechanism of action and use in clinical practice | New England Journal of Medicine | 2007 |
| Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system | Journal of Clinical Oncology | 2007 |
Shares Memorial Sloan Kettering Cancer Center, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
Shares Memorial Sloan Kettering Cancer Center, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
Shares American Society of Clinical Oncology (ASCO), HR-positive / HER2-negative breast cancer.
Shares American Society of Clinical Oncology (ASCO), HR-positive / HER2-negative breast cancer.
Shares American Society of Clinical Oncology (ASCO), HR-positive / HER2-negative breast cancer.
Shares Memorial Sloan Kettering Cancer Center, HR-positive / HER2-negative breast cancer.
Shares Memorial Sloan Kettering Cancer Center, HR-positive / HER2-negative breast cancer.
Shares Memorial Sloan Kettering Cancer Center, HR-positive / HER2-negative breast cancer.